KROS — Keros Therapeutics, Inc. stock price, charts and financials

Latest market price

10.75

-0.40-3.56%

Overview Short InterestFilings

KROSQT29Keros Therapeutics, Inc.·NASDAQ

Overview Short InterestFilings

10.75-3.56%

Loading chart...

Signal & projected range

Earnings miss — drift (PEAD)Historical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

AUPH-2.30%$15.48 MESO+4.92%$16.73 ZBIO-1.42%$31.97 GHRS-1.42%$29.84 TSHA-1.37%$6.47 STOK-1.63%$32.18 ABCL+33.62%$9.26 VRDN-3.11%$22.86

Snapshot

Index	-	P/E	-	EPS (ttm)	1.54	Insider Own	46.51%	Shs Outstand	32.00M	Perf Week	10.72%

Market Cap	356.78M	Forward P/E	-	EPS next Y	-6.09	Insider Trans	-0.15%	Shs Float	29.53M	Perf Month	-7.32%

Enterprise Value	114.90M	PEG	0.00	EPS next Q	-	Inst Own	-	Short Float	3.59%	Perf Quarter	-4.21%

Income	-134.40M	P/S	23.76	EPS this Y	-453.17%	Inst Trans	-	Short Ratio	3.44	Perf Half Y	-35.32%

Sales	15.01M	P/B	0.84	EPS next Y	-11.97%	ROA	-28.91%	Short Interest	1.06M	Perf YTD	-45.24%

Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-21.40%	52W High	21.74 -50.55%	Perf Year	-22.62%

Cash/sh	-	P/FCF	-	EPS past 3/5Y	-	ROIC	-35.25%	52W Low	9.34 15.07%	Perf 3Y	-72.12%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	94.69%	Volatility	5.66% 5.01%	Perf 5Y	-69.70%

Dividend TTM	-	EV/Sales	7.65	EPS Y/Y TTM	130.80%	Oper. Margin	-675.82%	ATR (14)	0.53	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	21.96	Sales Y/Y TTM	6050.00%	Profit Margin	-553.88%	RSI (14)	59.24	Recom	2.41

Dividend Gr. 3/5Y	-	Current Ratio	21.96	EPS Q/Q	-133.43%	SMA20	7.09%	Beta	1.01	Target Price	20.33

Payout	0.00%	Debt/Eq	0.06	Sales Q/Q	-100.00%	SMA50	4.86%	Rel Volume	1.10	Prev Close	11.15

Employees	78	LT Debt/Eq	0.05	Earnings	Nov 04	SMA200	-21.20%	Avg Volume	289.28K	Price	10.75

IPO Date	Apr 08, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-18.30% -80.97%	Net Debt/EBITDA	2.86	Volume	319,628	Change	-3.56%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Aug-04-26	Reiterated	H.C. Wainwright	Buy	$20
Aug-04-26	Reiterated	Leerink Partners	Outperform	$23
Aug-04-26	Reiterated	Wells Fargo	Overweight	$18
Jun-10-25	Downgrade	B of A Securities	Buy → Neutral
Jan-21-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-17-25	Downgrade	Wedbush	Outperform → Neutral
Dec-16-24	Downgrade	Guggenheim	Buy → Neutral
Dec-12-24	Downgrade	William Blair	Outperform → Market Perform
Dec-12-24	Downgrade	TD Cowen	Buy → Hold
Dec-12-24	Downgrade	BTIG	Buy → Neutral

Latest News

Aug-04-26

Aug-04-2611:45AM

KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focuszacks.com

09:20AM

Wells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $18Benzinga

Aug-03-26

Aug-03-2604:01PM

Keros Therapeutics Reports Second Quarter 2026 Financial Resultsglobenewswire.com

Jul-30-26

Jul-30-2604:04PM

Keros Therapeutics To Receive $20M Milestone Payment From Takeda Under Elritercept Licensing Terms After Dosing First Patient In The ELRiSE MDS TrialBenzinga

04:01PM

Keros Therapeutics to Receive Development Milestone Payment from Partner Takedaglobenewswire.com

06:06AM

New Strong Sell Stocks for July 30thzacks.com

Jul-22-26

Jul-22-2604:49PM

Keros Therapeutics CFO Keith Regnante Resigns, Effective Aug. 3; VP Finance Annita Tanini Named Interim Principal Financial OfficerBenzinga

Company

Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	246	244	4	—	—	—	—	—	—
Cost of Goods Sold Incl. D&A	0	2	0	—	—	—	—	—	—
Gross Profit	246	243	4	—	—	—	—	—	—
Selling, General and Administrative Excl. Other	45	47	41	—	—	—	—	—	—
Research and Development	159	130	174	—	—	—	—	—	—
Other Operating Expense	-2	-5	-1	—	—	—	—	—	—
Operating Income	44	71	-211	—	—	—	—	—	—
Interest Expense	0	0	0	—	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	28	21	24	—	—	—	—	—	—
Net Income Before Taxes	70	92	-187	—	—	—	—	—	—
Income Taxes	7	5	0	—	—	—	—	—	—
Consolidated Net Income	64	87	-187	—	—	—	—	—	—
Net Income From Continuing Operations	64	87	-187	—	—	—	—	—	—
Net Income	64	87	-187	—	—	—	—	—	—
EPS (Recurring)	1.58	2.34	-5.00	—	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	1.58	2.34	-5.00	—	—	—	—	—	—
EPS (Diluted)	1.54	2.30	-5.00	—	—	—	—	—	—
EBITDA	89	93	-186	—	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	6.98	8.85	—	—	—	—	—	—	—
Price To Sales Ratio	1.79	3.09	146.43	—	—	—	—	—	—
Gross Margin	100.00	99.59	100.00	—	—	—	—	—	—
Operating Margin	17.89	29.10	-5,275.00	—	—	—	—	—	—
Net Margin	26.02	35.66	-4,675.00	—	—	—	—	—	—
Shares Outstanding	41	37	37	—	—	—	—	—	—
Market Capitalization	441	753	586	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BIENAIME JEAN JACQUES	Director	Jul 15 '26	Buy	10.61	1,000	10,610	18,592	Jul 17
BIENAIME JEAN JACQUES	Director	Jun 15 '26	Buy	10.19	1,000	10,190	17,592	Jun 17
Newton Charles W.	Director	Jun 11 '26	Sale	10.04	550	5,522	12,665	Jun 15
Farzan Nima	Director	Jun 04 '26	Sale	10.73	2,625	28,166	9,767	Jun 08
Knowles Julius	Director	Jun 04 '26	Sale	10.73	2,625	28,166	10,958	Jun 08
Seth Alpna	Director	Jun 04 '26	Sale	10.72	2,625	28,140	9,767	Jun 05
BIENAIME JEAN JACQUES	Director	May 15 '26	Buy	10.58	1,000	10,580	9,450	May 19
BIENAIME JEAN JACQUES	Director	Apr 15 '26	Buy	11.70	1,000	11,700	8,450	Apr 17
Seehra Jasbir	CHIEF EXECUTIVE OFFICER	Apr 02 '26	Option Exercise	0.30	55,000	16,500	440,708	Apr 06
BIENAIME JEAN JACQUES	Director	Mar 09 '26	Buy	11.21	2,000	22,420	7,450	Mar 11
Seehra Jasbir	CHIEF EXECUTIVE OFFICER	Feb 19 '26	Sale	16.17	7,015	113,433	385,708	Feb 20
Lerner Lorena Raquel	Chief Science Officer	Feb 18 '26	Sale	16.35	3,873	63,324	31,127	Feb 20
Cho Esther	SVP, General Counsel	Feb 18 '26	Sale	16.35	4,745	77,581	39,755	Feb 20
Regnante Keith	CHIEF FINANCIAL OFFICER	Feb 18 '26	Sale	16.35	4,739	77,483	39,261	Feb 20
Pontifax Management 4 G.P. (2015) Ltd.	10% Owner	Oct 15 '25	Sale	17.75	155,262	2,755,901	0	Oct 17

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.